bims-tremyl Biomed News
on Therapy resistance biology in myeloid leukemia
Issue of 2026–11–22
sixteen papers selected by
Paolo Gallipoli, Barts Cancer Institute, Queen Mary University of London



  1. Blood Adv. 2026 Nov 20. pii: bloodadvances.2026020859. [Epub ahead of print]
      FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.
    DOI:  https://doi.org/10.1182/bloodadvances.2026020859
  2. Leukemia. 2026 Nov 17.
      European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.
    DOI:  https://doi.org/10.1038/s41375-026-03183-y
  3. Blood. 2026 Nov 16. pii: blood.2026034793. [Epub ahead of print]
      Sickle cell disease (SCD) affects millions globally, causing significant lifelong morbidity and early death. As childhood mortality is reduced and SCD patients are surviving to adulthood, increased risk of hematological malignancy (HM) is becoming evident. Risk of therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia, following gene therapy or hematopoietic stem cell transplant (HSCT) is also higher in SCD. The specific pathobiology that predisposes to HM is necessary to address, since survival has improved and gene therapy and HSCT are being increasingly used. We modelled the increased risk of HM in humanized SCD mice, compared to age-, sex- and strain-matched normal counterparts. We serially monitored hematopoiesis in blood and bone marrow up to 1-year-of-age and performed highly sensitive, error-corrected deep sequencing of 450 MDS/HM-associated genes. Unlike controls, SCD mice showed an 'ageing-like' phenotype with premature development of myeloid-biased hematopoiesis and hematopoietic stem/progenitor cells (HSPC) mutational profile characteristic of aged mice/humans. Furthermore, a high proportion of SCD mice developed hematopoiesis with dysplastic features reminiscent of MDS morphology and higher clonal hematopoiesis burden. Imposition of regenerative stress by serial HSCT further increased HSPC mutational burden, resulting in evolution/expansion of clones harboring oncogenic driver mutations. Our study indicates that increased HSC regenerative stress, imposed either by chronic erythropoietic demand or via autologous HSCT in SCD increases the risk of developing clonal hematopoiesis and MDS-like features. Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.
    DOI:  https://doi.org/10.1182/blood.2026034793
  4. Res Sq. 2026 Nov 10. pii: rs.3.rs-10568793. [Epub ahead of print]
      Pediatric acute myeloid leukemia (AML) is a devasting disease with 5-year survival outcomes of approximately 60%. Therefore, there is an urgent need to develop novel therapies for pediatric AML patients. Numerous studies have demonstrated that cellular metabolism is a key vulnerability in adult AML; however, metabolism in pediatric AML is less robustly characterized, limiting the development of metabolism targeting therapies for pediatric patients. We have previously shown that manipulation of polyamine metabolism offers a therapeutic window to target adult leukemia, but it is not known if pediatric AML is similarly sensitive. Using pediatric AML patient-derived xenograft models, we demonstrate that polyamine metabolism is a pharmacologically targetable vulnerability of pediatric AML cells. Further, depletion of polyamines sensitizes pediatric AML cells to chemotherapy in vitro and in vivo . Mechanistically, polyamine depletion reduces protein synthesis through decreased hypusination of translational elongation factor eIF5A. Pharmacologic polyamine depletion and inhibition of eIF5A hypusination result in reduced protein synthesis and decreased expression of cell cycle regulatory proteins resulting in a G 1 cell cycle arrest and eventual cell death through apoptosis. In summary, this study reveals polyamine metabolism and hypusination of eIF5A as a vulnerability in pediatric AML that can be targeted using clinically tractable approaches.
    DOI:  https://doi.org/10.21203/rs.3.rs-10568793/v1
  5. Blood Adv. 2026 Nov 20. pii: bloodadvances.2026021494. [Epub ahead of print]
      Advanced donor age is an established determinant of worse outcomes in allogeneic hematopoietic cell transplantation (HCT) using methotrexate/calcineurin inhibitor (CNI)-based graft-versus-host disease (GVHD) prophylaxis. But recent analyses of overlapping populations receiving post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis have reported different estimates of the magnitude and donor-type dependence of this association. Using a Center for International Blood and Marrow Transplant Research (CIBMTR) cohort, we analyzed 5,873 patients with acute leukemia or myelodysplastic syndrome undergoing first allogeneic HCT using matched unrelated (MUD) or haploidentical donors with PTCy. Outcomes included overall survival (OS), GVHD-free/relapse-free survival (GRFS), relapse, non-relapse mortality (NRM), acute GVHD, and chronic GVHD. We applied a hybrid analytical framework combining machine learning-based survival modeling (XGBoost) and multivariable Cox regression using generalized propensity score weighting. Considering MUD and haploidentical donors, each 10-year increase in donor age was associated with inferior OS (HR, 1.076; 95%CI, 1.030-1.124; p=0.001) and GRFS (HR, 1.098; 95%CI, 1.060-1.138; p<0.001) and higher risks of NRM and acute and chronic GVHD. Donor age was not significantly associated with relapse, and donor age-by-donor type interactions were not statistically significant. Model-estimated 24-month OS decreased from 63.3% at donor age 25 to 59.4% at age 45, and GRFS from 43.8% to 37.1%. Our findings provide an alternative characterization of donor-age associations in PTCy-based HCT and suggest that increasing donor age remains associated with adverse transplant outcomes without clear evidence of different effects between MUD and haploidentical donors.
    DOI:  https://doi.org/10.1182/bloodadvances.2026021494
  6. bioRxiv. 2025 Nov 03. pii: 2025.11.01.686055. [Epub ahead of print]
      The tumor microenvironment (TME) programs cancer cells to influence therapeutic responses. Macrophages residing in TME switch from pro-phagocytic to tumor-promoting and immunosuppressive phenotypes as cancer develops. While these pro-tumor functions of macrophages are associated with poor outcomes, the underlying mechanisms by which bone-marrow (BM)-associated macrophages fuel myeloid malignancy and their precise contribution to relapse remain undissected. Here, we show expansion of monocyte/macrophage population in leukemia patients post-chemotherapy relapse, and spatial proximity of macrophages to leukemia blasts in the BM niche. This proximity proved functionally consequential-depletion of macrophages delayed leukemia relapse post cytarabine (AraC), a frontline chemotherapy, in patient-derived xenografts (PDX) and syngeneic leukemia models. Mechanistically, a pyrimidine metabolite, deoxycytidine (dC), secreted by BM macrophages, is taken up by leukemia cells to directly inhibit deoxycytidine kinase (DCK) to hamper AraC activation and subsequent resistance in a cell non-autonomous manner. Diagnosis AML patients exhibited significantly higher circulating dC levels than healthy donors, and dC levels further increased following chemotherapy. SAMHD1, which catalyzes deoxynucleoside triphosphates (dNTPs) into deoxynucleoside, was highly abundant in macrophages and mediated dC accumulation. Blockade of dC production in mouse and human macrophages via genetic and pharmacological inhibition of SAMHD1 or DHODH , a critical enzyme in pyrimidine synthesis, restored AraC sensitivity. Combination with DHODH inhibitors significantly delayed AraC relapse in human PDX and mouse syngeneic AML models. Collectively, we identify a metabolic immune-leukemia crosstalk in which SAMHD1 high macrophages mediates chemoresistance by secreting pyrimidine metabolites and propose macrophage metabolic reprogramming as a tractable strategy to overcome TME-driven chemoresistance in myeloid leukemia.
    DOI:  https://doi.org/10.1101/2025.11.01.686055
  7. Clin Lymphoma Myeloma Leuk. 2026 Oct 21. pii: S2152-2650(26)04009-7. [Epub ahead of print]
       BACKGROUND: No dual inhibitors of isocitrate dehydrogenase 1 and 2 (IDH1/2) are available for the treatment of relapsed/refractory acute myeloid leukemia (AML). HMPL-306 is a potent, selective dual inhibitor of isocitrate dehydrogenase (IDH) 1 and IDH2. This phase 1 study evaluated the safety, efficacy, and pharmacokinetics of HMPL-306 in patients with IDH-mutant relapsed/refractory AML.
    METHODS: In the dose-escalation phase of the phase 1, open-label, multicenter study conducted in the United States and Spain (NCT04764474), patients with IDH-mutant relapsed/refractory AML were enrolled into 8 dosing cohorts and received HMPL-306 50-400 mg once-daily orally. The primary endpoints were maximum tolerated dose (MTD) and/or recommended phase 2 dose and safety.
    RESULTS: Forty-six patients were enrolled and received treatment (median age, 71 years; IDH1 mutation, 41.3%; IDH2 mutation, 56.5%; IDH inhibitor-previously treated, 26.1%). No dose-limiting toxicities occurred and MTD was not reached. Treatment-related adverse events occurred in 39.1% of patients, most commonly (≥ 5%) thrombocytopenia (10.9%), differentiation syndrome (8.7%), and alanine aminotransferase increased (6.5%). At doses ≥ 150 mg (n = 35), the objective response rate was 48.6%, with median duration of objective response of 3.71 months; the rate of complete response (CR) with negative minimal residual disease, CR, and CR with partial hematological recovery was 34.3%. Antitumor activity was shown in both IDH1- and IDH2-mutant subgroups. Population pharmacokinetic-pharmacodynamic modeling demonstrated maximum target inhibition at ≥ 150 mg.
    CONCLUSIONS: HMPL-306 demonstrated a manageable safety profile and promising antitumor activity in patients with IDH1- or IDH2-mutant relapsed/refractory AML.
    CLINICAL TRIAL REGISTRATION: NCT04764474.
    Keywords:  Antitumor activity; Isocitrate dehydrogenase inhibitor; Relapsed/refractory acute myeloid leukemia; Safety
    DOI:  https://doi.org/10.1016/j.clml.2026.10.016
  8. Blood Adv. 2026 Nov 18. pii: bloodadvances.2026021475. [Epub ahead of print]
      Chronic myeloid leukemia (CML) has an excellent prognosis with tyrosine kinase inhibitors (TKIs); however, approximately 40-50% of patients discontinue at least one TKI because of resistance or intolerance. While Ponatinib (PON) is highly effective against resistant disease, Asciminib (ASC) offers robust efficacy with favorable tolerability profile. In the absence of randomized head-to-head trials, we compared outcomes of ASC versus PON using propensity score-matched (PSM) analysis. We conducted a real-world analysis of 762 CML patients previously treated with ≥1 TKI (ASC, n=451; PON, n=311), from an international multicenter cohort. PSM generated 139 balanced pairs after adjusting for age, prior TKI exposure, cardiovascular history, ABL kinase domain mutations, and reason for prior TKI failure. The primary endpoints, evaluated in the matched cohort, were 12-month failure-free survival (FFS) and event-free survival (EFS). ASC was associated with similar molecular response rates and FFS to PON, while EFS was significantly longer with ASC, likely reflecting its more favorable tolerability and lower rate of discontinuation due to intolerance. The difference in EFS was particularly pronounced among patients treated for prior TKI intolerance and in lower-risk subgroups. A sensitivity analysis restricted to patients naïve to both agents (117 matched pairs) confirmed the EFS difference (12-month EFS, 88.6% vs 73.2%; HR 2.48; p=0.002). ASC was associated with similar molecular response and FFS outcomes to PON These findings suggest that ASC was associated with similar real-world molecular response and FFS outcomes to PON, while EFS was longer with ASC, largely driven by differences in treatment discontinuation related to intolerance. ASC may represent an attractive option for patients with prior TKI intolerance, while PON remains an important treatment option for patients with resistant disease.
    DOI:  https://doi.org/10.1182/bloodadvances.2026021475
  9. Blood Adv. 2026 Nov 20. pii: bloodadvances.2026021619. [Epub ahead of print]
      Myelofibrosis (MF) is a Philadelphia-negative clonal disorder of hematopoietic stem cells associated with substantial clinical practice variation. The American Society of Hematology (ASH) convened a guideline panel that prioritized ten clinical questions to inform evidence-based recommendations. We performed a comprehensive systematic review of MEDLINE, EMBASE, Cochrane databases, and Scopus through January 2025 to identify studies that addressed the ten clinical questions. Meta-analyses were performed where feasible. Two reviewers independently selected and appraised studies. Certainty of evidence was assessed using GRADE. Of 3,007 records screened, 43 unique studies met inclusion criteria for the ten questions. Extended molecular testing identified high-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2) that were significantly associated with decreased overall survival (hazard ratios ranging 1.5-4.5). JAK inhibitors improved spleen and symptom responses in symptomatic lower-risk MF and in patients with anemia, with momelotinib improving transfusion independence. However, survival effects were not clearly demonstrated and hematologic toxicity remained common. Evidence for treating asymptomatic high-risk patients with JAK inhibitors was particularly limited. Early allogeneic hematopoietic cell transplantation was associated with higher early mortality but improved long-term survival compared with delayed transplantation. Pretransplant JAK inhibitor exposure did not significantly affect mortality, GVHD, or graft failure. Evidence for interferon, aspirin, and iron chelation was limited and largely indirect. The certainty of evidence was very low or low across nearly all outcomes.
    DOI:  https://doi.org/10.1182/bloodadvances.2026021619
  10. Bone Marrow Transplant. 2026 Nov 17.
    Chronic Malignancies Working Party of the EBMT
      The role of haploidentical hematopoietic cell transplantation (haplo-HCT) in myelofibrosis (MF) remains debated. This EBMT registry-based study included 263 MF patients who underwent haplo-HCT between 2012 and 2020 using peripheral blood (PB; n = 163) or bone marrow (BM; n = 100) grafts. BM was more commonly used in earlier transplant eras and was associated with higher rates of prior splenectomy, myeloablative conditioning, and lower HCT-CI scores. Cumulative incidence of primary graft failure (GF) was higher with BM than PB (12% vs. 4%; p = 0.02), whereas secondary GF at 1 year was similar (8% vs. 10%). Among PB recipients, a higher CD34+ cell dose ( ≥ 7 × 10⁶/kg) was significantly associated (p = 0.009) with faster neutrophil recovery (median 20 vs. 25 days) and higher day-28 engraftment (83% vs. 65%). No such association was observed in the BM group. After a median follow-up of 42 months, 4-year overall survival, progression-free survival, relapse incidence, and non-relapse mortality were 51%, 41%, 23%, and 36%, respectively, with no significant differences between groups. GF remains a major challenge in haplo-HCT for MF, particularly with BM grafts. Higher CD34+ cell doses may improve neutrophil recovery following PB transplantation. Interpretation of long-term outcome comparisons is limited by substantial baseline differences between the study groups.
    DOI:  https://doi.org/10.1038/s41409-026-03018-5
  11. Proc Natl Acad Sci U S A. 2026 Nov 24. 123(47): e2630773123
      Leptin Receptor-expressing (LepR+) stromal cells in the bone marrow are a critical source of growth factors for the maintenance of hematopoietic stem cells (HSCs) and most restricted hematopoietic progenitors. An important unresolved question is whether they also regulate terminal differentiation in some hematopoietic cells. We found that bone marrow LepR+ cells promote thrombopoiesis by synthesizing the chemokine CXCL14. Cxcl14-expressing LepR+ cells extend fine processes that wrap around perisinusoidal megakaryocytes. Deletion of Cxcl14 from LepR+ cells did not significantly alter HSC function or most aspects of bone marrow hematopoiesis, including megakaryocyte generation; however, it significantly reduced the numbers of proplatelet-forming megakaryocytes in the bone marrow and platelets in the blood, as well as platelet quality. Megakaryocytes from Lepr-cre; Cxcl14 fl/fl mice expressed lower levels of genes that encode granule proteins as compared to control mice, leading to the release of platelets with fewer α-granules and defective thrombus formation/growth. CXCL14 promoted platelet formation by remodeling lipid metabolism in megakaryocytes, increasing fatty acid transporter expression and enabling megakaryocytes to take up more polyunsaturated fatty acids from circulation. A high fat diet rescued the formation of proplatelet-forming megakaryocytes and platelets, as well as platelet function, in Lepr-cre; Cxcl14 fl/fl mice. CXCL14 protein was sufficient to promote platelet formation by megakaryocytes in vitro and in vivo. LepR+ cells thus create a perisinusoidal niche for thrombopoiesis by producing CXCL14, which regulates lipid metabolism and terminal differentiation in megakaryocytes.
    Keywords:  Cxcl14; megakaryocyte; niche; platelet; thrombopoiesis
    DOI:  https://doi.org/10.1073/pnas.2630773123
  12. Blood Neoplasia. 2026 Nov;3(4): 100289
      The hallmark of chronic myelomonocytic leukemia (CMML) is an abnormal increase in circulating monocytes and neutrophils. Several nonexclusive scenarios could explain this accumulation, including extended life span in blood and/or increased production in bone marrow (BM). To test these, we generated quantitative in vivo measurements of how myeloid cells are produced, mature, and survive by using deuterium-labeled glucose incorporation, mathematical modeling, and Bayesian inference in 25 patients with CMML and 10 healthy donors aged 55 years or older. Results showed no evidence of increased life span of monocytes and neutrophils in peripheral blood. Conversely, CMML boosts the production of monocytes by approximately sevenfold and neutrophils by ∼1.8-fold. The lack of correlation between this increased production and cell subset kinetic parameters supports the hypothesis that an increased number of progenitors is the main source of enhanced myeloid cell production. Beyond this generic observation, kinetic parameters were more divergent in patients with CMML than in controls. The most divergent outlier participants tended to have higher Molecular International Prognostic Scoring System scores for myelodysplastic syndromes. Delayed maturation of neutrophils was observed in patients with SRSF2 mutation, whereas BM retention of mature monocytes and neutrophils was diversely associated with inflammatory markers. Occasionally, patients with CMML release immature granulocytes (iGRANs) into the circulation. We found that these iGRANs had distinct kinetics, including delayed maturation, rapid release, and longer survival in the bloodstream. Overall, these data support a model in which increased myeloid cell production stems from greater progenitor numbers, generating cells with increasingly diverse kinetics as the disease progresses, including a specifically dysregulated iGRAN population. This trial was registered at www.clinicaltrials.gov as NCT04775121.
    DOI:  https://doi.org/10.1016/j.bneo.2026.100289
  13. Blood Adv. 2026 Nov 20. pii: bloodadvances.2026020796. [Epub ahead of print]
      FLT3 mutations presented in 30% of acute myeloid leukemia (AML) patients and correlate with high relapse rates and poor prognosis. Resistance mutations and central nervous system (CNS) involvement remain major challenges despite clinical FLT3 inhibitors. This study evaluated the preclinical efficacy and safety of STI-8591, a novel kinase inhibitor, in FLT3-mutant (FLT3 mut)AML, focusing on the FLT3-ITD-F691L resistance mutation and CNS leukemia models to support clinical translation. STI-8591 was tested in FLT3 mut human AML cell lines (MV4-11, MOLM-13), murine Ba/F3 cells expressing various FLT3 mutants (D835Y, ITD-D835Y, ITD-F691L), and primary AML blasts. Effects on proliferation, apoptosis, cell cycle, colony formation, and FLT3 signaling were assessed. Five in vivo models were used: Ba/F3-FLT3 mutant xenograft, MllPTD/WT:Flt3ITD/ITD transgenic, MOLM-13 CDX, CNS leukemia CDX, and chemoresistant PDX models. Pharmacokinetics and toxicology were evaluated in mice, rats, and dogs. In vitro, STI-8591 potently inhibited proliferation of FLT3 mut cell lines (IC50: 1.94-10.82 nM) and primary blasts (de novo IC50: 3.37-160.50 nM; relapsed/refractory IC50: 12.4-800.3 nM), induced G0/G1 arrest and apoptosis, and blocked FLT3/STAT5/AKT/ERK phosphorylation. In patient-derived CD34⁺blasts, 40 nM STI-8591 reduced colony formation by 94%. Orally administered STI-8591 (3-30 mg/kg) significantly suppressed leukemia progression and prolonged survival in all models. Notably, it maintained efficacy against the FLT3-ITD-F691L gatekeeper mutation, outperforming Gilteritinib, and showed activity in CNS leukemia and chemoresistant PDX models. PK/toxicology studies demonstrated favorable profiles without unexpected adverse effects. STI-8591 is a promising therapeutic agent for FLT3 mut AML, including resistant subtypes and CNS involvement.
    DOI:  https://doi.org/10.1182/bloodadvances.2026020796
  14. Nat Commun. 2026 Nov 20. pii: 11677. [Epub ahead of print]17(1):
      Germline mutations in PARN cause dyskeratosis congenita (DC), an inherited bone marrow failure syndrome characterized by multilineage cytopenia and progression to myeloid disease. The mechanisms underlying this malignant transformation have not been fully elucidated. Here we show, using a loss-of-function CRISPR-Cas9 zebrafish parn mutant, hematopoietic stem and progenitor (HSPC) expansion and reduced mature hematopoietic cells across various lineages. Cholesterol biosynthesis was transcriptionally activated; a finding recapitulated in patient-derived iPSCs with PARN mutations. Inhibiting cholesterol biosynthesis rescued HSPC expansion and anemia in parn mutants. Concurrent myeloid differentiation therapy or Wnt inhibition reduced HSPCs to varying degrees. We further demonstrate a role for activated Erk signaling in impairing erythrocyte differentiation and show robust rescue with trametinib treatment. Overall, our findings uncover unrecognized roles for Parn in regulating cholesterol metabolism and Erk signaling and provide preclinical evidence for targeting these pathways to restore hematopoiesis in DC.
    DOI:  https://doi.org/10.1038/s41467-026-79105-4
  15. Blood. 2026 Nov 16. pii: blood.2026034453. [Epub ahead of print]
      Chronic graft-versus-host disease (cGVHD) contributes substantially to morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients. Microbe-derived short-chain fatty acids (SCFA) exert diverse local effects on the intestinal mucosa. We previously reported that a relative deficiency of SCFA in the circulation of transplant patients was associated with an increased incidence of cGVHD. We therefore hypothesized that circulating SCFA were unrecognized immunomodulators, generating protective effects after transplantation. We examined the role of SCFA butyrate and propionate in mouse models of cGVHD and now report that systemic administration of either butyrate or propionate mitigates cGVHD and improves survival. Exogenous SCFA treatment reduced pathogenic hyperexpanded B cells and recipient-specific IgA in the circulation, as well as decreasing the total alloantibody pool, defined using rapid extracellular antigen profiling (REAP). Our findings uncover a mechanism by which the intestinal microbiome plays a role in regulating antibody-dependent cGVHD pathogenesis and has implications for other antibody-mediated pathologies.
    DOI:  https://doi.org/10.1182/blood.2026034453
  16. Mol Cell. 2026 Nov 17. pii: S1097-2765(26)00756-2. [Epub ahead of print]
      Histone acetylation is tightly correlated with active transcription, yet its causal roles and downstream mechanisms remain incompletely defined. Chromosomal translocations generating fusion proteins involving histone acetyltransferases (HATs) represent a powerful but underexplored system to dissect how dysregulated acetylation rewires transcriptional control. Here, we establish an endogenous mouse model of acute myeloid leukemia (AML) driven by a fusion between two HATs, KAT6A and p300, generated through CRISPR-mediated chromosomal rearrangement. KAT6A-p300 induces aggressive, transplantable AML and confers oncogene addiction. Mechanistically, the fusion establishes broad promoter-associated hyperacetylated domains. This hyperacetylation promotes recruitment and remodeling by the canonical BAF complex, increasing promoter accessibility and stimulating RNA polymerase II recruitment and transcription initiation. Fusion formation also redistributes wild-type p300, broadens its chromatin occupancy, and stabilizes its association with fusion-bound loci. Together, our findings establish histone hyperacetylation as a driver of transcription and reveal a direct mechanistic link between aberrant acetylation, chromatin remodeling, and leukemogenesis.
    Keywords:  KAT6A-p300; RNA polymerase II; acute myeloid leukemia; canonical BAF; chromatin remodeling; histone acetylation; transcription initiation
    DOI:  https://doi.org/10.1016/j.molcel.2026.10.036